Blue Matter Blog

File and Don’t Forget: Securing Intellectual Property Protection and Completing Regulatory Filings
January 20, 2020

When entering European markets, a biopharma company must do a range of important things, many of which we will address throughout this series. In this installment, we cover two foundational elements of any European market entry that can set the commercial playing field for years to come.  They are 1.) Securing intellectual property (IP) protection …

Blue Matter Breakfast Club Meeting #3 – A Discussion with Theresa Heggie of Alnylam Pharmaceuticals
November 8, 2019

The Blue Matter Breakfast Club is an ongoing series of quarterly two-hour breakfast forums, hosted by our Rare Diseases Team.  These forums bring together leaders from companies that develop and commercialize rare disease therapies to discuss critical business issues. The third Breakfast Club meeting was on 5th November 2019 at Skylounge restaurant in Zug, Switzerland.  …

Seven Keys to Success in Europe
August 26, 2019

For US-based biopharmaceutical companies seeking to expand, establishing a presence in Europe is usually an obvious next step.  Investors typically expect that a company will avail itself of such a large market opportunity and unlock the full commercial value of its assets. Europe represents the second largest market in the world for prescription pharmaceuticals.  The …